drugset
Drugs / Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli)
last change Nov 2024 re-read 3 minutes ago

Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli)

also known as Cecolin · HPV

Vaccine

Developed for
cervical cancer · cervical intraepithelial neoplasia · human papilloma virus infection · intraepithelial neoplasia · vulvar intraepithelial neoplasia
Investigated by
Dongtai City Centers for Disease Control and Prevention · Jiangsu Province Centers for Disease Control and Prevention · Xiamen Innovax Biotech Co., Ltd · Zhejiang Provincial Center for Disease Control and Prevention

Trials 2

today NCT05279248 · Ph 4 NCT05426148 · Ph 4
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT05279248 Aug 2021 → Dec 2022 human papilloma virus infection, measles, mumps infectious disease, rubella Zhejiang Provincial Center for Disease Control and Prevention Unknown No outcome recorded
Phase 4 NCT05426148 May → Aug 2020 cervical cancer, cervical intraepithelial neoplasia, intraepithelial neoplasia, vulvar intraepithelial neoplasia Xiamen Innovax Biotech Co., Ltd Completed No outcome recorded

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2024-11-26 Xiamen Innovax Biotech Co., Ltd Results 2024IPVC圆满落幕，Cecolin®闪耀国际舞台！ innovax.cn ↗

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 5 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) “The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles...” NCT05279248 ↗
1

NCT05426148 ↗
Known as Cecolin “Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) / Cecolin®” NCT05426148 ↗
Known as HPV “The purpose of this study is to evaluate the immunogenicity and safety of Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli) （HPV）and Measles...” NCT05279248 ↗
Modality Vaccine “Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (Escherichia coli)” NCT05279248 ↗
Route Intramuscular “Participants would receive 2 doses of Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Escherichia coli) intramuscularly at 0, 6 month.” NCT05426148 ↗